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Goal-directed therapy for RA in routine practice is
associated with improved function in patients with
disease duration up to 15 years
SIR, Improved therapies have dramatically increased our
ability to suppress RA disease activity. Short-term goal-
directed therapy or treat-to-target, central to the manage-
ment of hypertension and diabetes, may be the next step
to increase effectiveness of RA therapy, although recent
recommendations for treat-to-target strategies acknow-
ledge the limited data from routine care (RC) [1].
Nevertheless, inducing remission is a logical short-term
goal in RA [2, 3]. Patients receiving DMARDs and achiev-
ing low disease states have less joint damage progression
[4, 5]. Patient preferences for therapy outcomes consist-
ently identify their priorities as reduced pain and mainten-
ance of function [6, 7]. Our RA Centre service routinely
uses goal-directed therapy (GDT) strategy, short-term
goal DAS-28 remission (DAS-28<2.6). After 2 years, we
tested if this strategy improved patient function, compar-
ing RA Centre outcomes with those of clinics in the
same hospital not using this strategy.
An RC group of consecutive patients recruited from
clinics where treatment aimed to reduce signs and
symptoms with no precise goal, was compared with a
matched sample of RA Centre patients, the GDT group.
The Guy’s Hospital Research Ethics Committee approved
the study and patients gave informed consent. Patients
with RA (ACR 1987 revised criteria) [8] over the age of
18 years were recruited for assessment, with no disease-
or comorbidity-related exclusion criteria. Groups were
matched within disease duration2 years, age5 years
and sex. Rheumatologists treating the RC group were not
aware of the patient DAS-28 score. HAQ-Disability Index
(DI) was not used to guide treatment in either clinic. RC
patients were assessed on a single occasion with joint
counts and global disease activity performed by a re-
search nurse not involved in therapy decisions. Fisher’s
exact tests were used for categorical data, and Wilcoxon
signed rank sum tests for paired continuous data, almost
all non-normally distributed. Multiple logistic regression
assessed clinical factor contributions to achieving
remission, and multivariable linear regression assessed
influences on HAQ. Analyses were performed using
SPSS 15.0 and Graph Pad Prism 5.
Ninety patients were recruited to the RC group and
data compared with that collected contemporaneously
from matched GDT patients. More GDT patients received
combination DMARDs (12 vs 3%, P=0.048) but not bio-
logics (20 vs 13%, P=0.32). Multiple regression analysis
identified DAS-28, age, disease duration and pain VAS as
independent predictors of HAQ-DI, with the highest con-
tribution from DAS-28. Patients in the GDT group with
disease duration up to 15 years showed significantly im-
proved function compared with RC, with increasingly
large differences in patients with shorter disease duration
(Fig. 1A). Significantly more GDT patients achieved remis-
sion at all disease duration periods (Fig. 1B). Multiple
logistic regression including all patients (disease duration
up to 30 years) showed males were less likely to achieve
remission [odds ratio (OR) 0.3; 95% CI 0.1, 0.8], and pa-
tients without erosions were more likely to achieve
FIG.1Goal-directed therapy increases the numbers of patients in remission and reduces HAQ in patients up to disease
duration of 15 years. (A) Median HAQ is significantly lower in the GDT group at a range of disease durations.
(B) Remission was defined by DAS-28<2.6; increased numbers of patients were in remission at all disease durations
in the GDT group. *P<0.05, **P<0.01.
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ease duration up to 15 years, only GDT was influential in
achieving remission (OR 5.7; 95% CI 1.5, 21.7).
This study of outcomes in routine hospital clinics using
standard medication regimens shows that a DAS-28
goal-directed strategy is associated with significantly im-
proved function for patients with disease duration up to
15 years. DAS-28 remission achievers had significantly
better HAQ scores compared with non-achievers.
DAS-28 remission rates were significantly better in the
GDT group with RA >15 years, but HAQ scores were
not better. This may reflect clinical trial results, where
patients with longer disease duration have smaller HAQ
improvements despite similar DAS-28 improvements [9].
Secondly, GDT patients with disease up to 5 years,
receiving 2 years of GDT, achieved much higher remission
rates (39%) compared with RC patients (9%).
We assessed unselected patients attending routine out-
patient clinics. As such, these results are relevant to gen-
eral rheumatology clinic populations. In contrast to most
studies of goal-directed therapy studying early arthritis,
our patients had longer disease duration. We also dem-
onstrate the challenges of achieving remission in un-
selected populations. Many patients declined increases
in therapy or had co-morbidities preventing intensified
therapy. Our patients were not selected by consenting
to a treatment protocol, and therapy decisions were
the usual consensus of rheumatologist advice, assessed
from the patient’s perspective. The concept of patient ac-
ceptable symptom state (PASS) may explain this reluc-
tance. A large study of RC patients, with a mean
disease duration of 7.6 years, showed that the DAS-28
score cut-off for PASS status was 4.05 [10]. Additionally,
in the UK, biologic therapy is only available for patients
with DAS-28>5.1. In conclusion, a goal-directed or
treat-to-target strategy can be successfully utilized in
RC to achieve higher remission rates, and is associated
with better function in patients with early and medium dis-
ease duration. HAQ-DI for patients in remission was sig-
nificantly lower than those not in remission, suggesting
that DAS-28 remission is a relevant goal to improve
function.
Rheumatology key message
. Treating to target in RA in routine practice is asso-
ciated with improved function.
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Streptococcal hypersensitivity reloaded: severe
inflammatory syndrome in Behc ¸et’s disease
following 23-valent polysaccharide Streptococcus
pneumoniae vaccine
SIR, Infections with Streptococcus pneumoniae are a
significant cause of morbidity and mortality in patients
with autoimmune inflammatory rheumatic diseases. The
European League Against Rheumatism (EULAR) recom-
mends the 23-valent polysaccharide pneumococcal
vaccine (23-PPV) in patients with inflammatory rheumatic
diseases, including Behc ¸et’s disease (BD) [1]. Pneu-
mococcal vaccine safety was tested in RA, juvenile arth-
ritis and SLE [2] and no significant local or systemic
adverse events and disease flares were reported.
We have recently implemented the EULAR recommen-
dations in our outpatient service by systematically vacci-
nating patients with autoimmune inflammatory rheumatic
diseases if they are treated with immunosuppressive
agents. Subsequently we have observed four patients
with BD who developed severe local reactions to the
first application of 23-PPV at the injection site as well as
a severe systemic inflammatory response. No systemic
adverse reactions were observed in patients of our service
who received 23-PPV for autoimmune conditions other
than BD.
The clinical features of the four patients are summarized
in Table 1. The three male patients fulfilled the criteria for
BD and the female patient had an incomplete phenotype
of BD with oral ulcers, oligoarthritis and HLA-B51 geno-
type positivity. The mean disease duration of BD was
9.5 years. All of the patients had been vaccinated against
influenza and tetanus without complication, one also had
received hepatitis A and tick-borne encephalitis vaccines
without adverse reactions. The local adverse reaction to
the 23-PPV originating from different charges was similar
in all of the patients and developed 48h after the injec-
tion, with pain, redness and local swelling (spreading
15cm from the injection site); urticarial lesions were
not observed. Whereas the local symptoms resolved com-
pletely after 1 day in the female patient, the three males
developed a severe systemic inflammation with malaise,
high fever, chills and vomiting. Leucocyte counts in-
creased to a maximum of 20.510
9/l and the CRP to
385mg/l. All symptoms resolved in a few days with local
cooling, paracetamol, anti-inflammatory non-steroidal
drugs and i.v. fluids. In one patient, the initially diffuse
swelling at the injection site, which extended from the
acromion to the elbow, turned into a profound pseudofol-
liculitis, prior to complete resolution (supplementary
figure).
There are several possible explanations for this severe
adverse reaction. Pneumovax 23 is the currently licensed
pneumococcal polysaccharide vaccine. A 0.5ml dose of
this vaccine contains 25mg of polysaccharides from the
23 most prevalent or invasive pneumococcal types in iso-
tonic saline, plus 0.25% phenol as preservative. Minor
local injection reactions are frequently observed, whereas
the incidence of severe vaccine-related systemic adverse
events is low. Phenol is used in many vaccines as a pre-
servative with low immunogenic properties. It is therefore
unlikely that phenol contributed to the adverse reactions.
BD is considered an autoinflammatory multisystem dis-
ease. An overreacting immune system with neutrophil
hyperfunction, also described as pathergy, is frequently
encountered. For pathergy testing, a sterile needle is
used to obliquely penetrate the skin, provoking a local
induration after 48h. Pathergy-like inflammatory reactions
can also be triggered by insults such as trauma, athro-
centesis or surgery, and then affect organs other than
the skin [3]. However, three of the reported patients here
had negative pathergy testing.
In patients with BD, elevated antibody titres directed
against streptococci in the oral flora have been detected
and skin hypersensitivity against streptococci has been
included in the Japanese diagnostic criteria for BD [4].
An immune reaction to one or several of the 23 polysac-
charides by pre-existing anti-streptococcal antibodies or
an IgE-mediated anaphylactic reaction could therefore ex-
plain some symptoms of the patients, although the time
course and the clinical features make the latter pathome-
chanism unlikely. The systemic inflammatory reactions in
our cohort contrast to reports of local BD symptoms that
occurred after streptococcal antigen exposure [5]. This
divergence may be accounted by the obvious difference
in the streptococcus species, as well as by different
amounts of antigen and route of exposure. Interestingly,
the mildest reaction was observed in the patient with in-
complete BD who only received ibuprofen. To what extent
etanercept, abatacept or AZA further influenced the
symptoms in the other three patients remains speculative
at this point.
More recently, BD has been proposed as an autoinflam-
matory disease secondary to an aberrant activation of the
inflammasome, a complex modular structure that acti-
vates IL-1b [6]. In this context, it is interesting to note
that 23-PPV can activate toll-like receptors (TLRs) 2 and
4 as known triggers of sterile inflammation [7]. TLR trig-
gering by 23-PPV components with subsequent inflam-
masome activation via IL-1b in a predisposed host could
explain the rapid onset of the adverse reaction, the occur-
rence of high fever and the neutrophilic nature of the sys-
temic inflammatory response. Our observations may also
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